Abstract: Recombinant, alive and metabolically active bacteria including a heterologous prokaryotic biomineralized ferritin. In particular, the inventors have shown that naturally non-magnetic Escherichia coli may be engineered to become magnetic by the expression and the biomineralization of the ferritin of Pyrococcus furiosus. Moreover, the inventors have shown that a fixed number of magnetic E. coli strains keep their magnetic properties through cell division by asymmetrical division. The inventors have also shown that magnetic bacteria according to the invention may be of use in both non-therapeutic and therapeutic uses, such as, e.g., the biosensing of target substance, the depollution of complex environments, the display of antibodies, nanobodies and antigens, the delivery of therapeutic substance to target cells, the targeting and infection of target cells.

Abstract: The present disclosure relates to 2,6-diaminopurine (DAP) for use in the treatment of a disease caused by a nonsense mutation in a gene, leading to the premature insertion of a UGA stop codon.

Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH)enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.

Abstract: Disclosed is a force sensor, including: at least one measurement cell, each measurement cell being filled with a filling material in which at least one inclusion of a substance is embedded; for each cell, at least one light source arranged in order to illuminate the inclusion embedded in this cell; for each cell, a measurement system including at least one optical measurement point arranged in order to capture light originating from the inclusion embedded in this cell; for each cell, a unit arranged in order to convert optical signals originating from the measurement system of this cell to a signal representative of a force exerted on this cell, this signal being dependent on a movement of the inclusion embedded within the filling material of this cell.

Abstract: The present disclosure relates to 2,6-diaminopurine (DAP) for use in the treatment of a disease caused by a nonsense mutation in a gene, leading to the premature insertion of a UGA stop codon.

Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.

Abstract: Disclosed is a force sensor, including: at least one measurement cell, each measurement cell being filled with a filling material in which at least one inclusion of a substance is embedded; for each cell, at least one light source arranged in order to illuminate the inclusion embedded in this cell; for each cell, a measurement system including at least one optical measurement point arranged in order to capture light originating from the inclusion embedded in this cell; for each cell, a unit arranged in order to convert optical signals originating from the measurement system of this cell to a signal representative of a force exerted on this cell, this signal being dependent on a movement of the inclusion embedded within the filling material of this cell.

Abstract: The invention relates to a method for generating control commands for coordinating displacement members of a moving platform, so as to make said moving platform progress between an initial speed and a final speed according to at least two locomotive situations.

Abstract: The invention relates to a method for generating control commands for coordinating displacement members of a moving platform, so as to make said moving platform progress between an initial speed and a final speed according to at least two locomotive situations.

Abstract: The present disclosure provides in vitro methods of diagnosing a Plasmodium infection in a subject. The methods include measuring the serum concentration of at least one secreted phospholipase A2 selected from the group consisting of GIIF, GV and GX sPLA2s, in a blood sample from the subject. The disclosure also relates to a kit for carrying out the disclosed methods and pharmaceutical compositions comprising a recombinant mammalian GIIF, GV or GX sPLA2, or a combination thereof.

Abstract: The invention relates to transgenic aquatic animals, particularly the clawed frog and the zebra fish and cells derived therefrom, characterized in comprising at least one expression cassette with a regulatory DNA sequence selected from the response elements to nuclear hormone receptors, particularly TRE, connected in a functional manner downstream of a DNA segment coding for a marker protein such as luciferase or GFP. The invention further relates to methods using the transgenic cells and animals according to the invention for the identification of endocrine disrupters in the environment.

Abstract: The present invention relates to an in vitro method of diagnosis of a Plasmodium infection in a subject, by measuring the serum concentration of at least one secreted phospholipase A2 selected from the group consisting of GIIF, GV and GX sPLA2s, in said subject, from a blood sample. It also relates to a kit for carrying out said method and pharmaceutical compositions comprising a recombinant mammal GIIF, GV or GX sPLA2 or a combination thereof.

Abstract: The present invention relates to a method for extracting organic molecules and/or organic minerals from a limestone material, including placing said limestone material in contact with a solution including at least one organic solvent, water and at least one acid, as well as to the organic molecules and/or organic minerals produced by the method. The products produced by the method can be used, for example, in therapeutic and non-therapeutic fields, in particular the agri-food, cosmetic and medical fields.

Abstract: The invention relates to compositions and methods for interfering with the DNA repair of double strand breaks (DSBs). The invention discloses double-stranded nucleic acid molecules that act as baits and hijack the holocomplex of enzymes responsible for DNA DSB sensing, signaling and/or repair pathways, in particular the non-homologous end joining (NHEJ) pathway of DSB repair. The invention discloses the use of these molecules as a standalone anticancer drug in an efficient amount to be introduced in the tumor cell nuclei in order to trigger their death.

Abstract: The invention relates to xanthone derivatives of formula (IA) or (IB) and their use for manufacturing a medicament for cancer, and in particular for chemotherapeutic resistant cancer. More particularly, the invention relates to compounds and compositions comprising such xanthone derivatives for the prevention and/or treatment for chronic leukemia and, for example, for chronic lymphocytic leukemia (CLL) or B-lymphoma.

Abstract: The present invention relates to Penta-hexa-, hepta-, octa-, nona- and, deca-heteroaryl derivatives, comprising a combination of heterocycle 1 (Het-1)a and/or heterocycle 2 (Het-2)b and/or heterocycle 3 (Het-3)c and/or heterocycle 4 (Het-4)d of formulae I, II, III and IV respectively, the N-oxides, the pharmaceutically acceptable addition salts. The compounds claimed are suitable for the treatment of cancer.

Abstract: Anti-malarial alkyloid compounds have the formula: wherein R1-R11 have various disclosed values or their pharmaceutically acceptable salts, and pharmaceutical compositions containing the same.

Abstract: The invention relates to a Microbulbifer bacterial strain isolated from a marine sponge, to its use in a process for manufacturing paraben compounds. The invention also relates to paraben compounds obtained from that Microbulbifer strain and to their uses. The Microbulbifer strain of the invention is Microbulbifer strain named L4-N2 deposited at the CNCM under the registration number 1-3714. The process of manufacturing paraben compounds of the invention makes use of this Microbulbifer strain. The invention finds application in the manufacture of paraben compounds, for use in particular in cosmetic, pharmaceutical, antifouling, detergent, sanitizing and disinfectant compositions.

Abstract: The present invention relates to an anti-gene oligonucleotide which hybridizes specifically with the gene encoding human tyrosinase by Hoogsteen pairing between the complementary bases, said oligonucleotide forming a triple helix structure with the human tyrosinase gene. The invention also relates to the use of said oligonucleotide as a skin-depigmenting or skin-bleaching agent in a cosmetic composition or in a dermatological composition.

Abstract: The invention relates to double-stranded nucleic acid fragments comprising a chemically modified backbone and at least 4-1000 bp, preferably 8-500 bp, and most preferably 16-200 bp. The disclosed molecules (DRIL molecules) may interfere with DNA damage signaling and repair pathways, in particular the non homologous NHEJ pathway of double-stranded break repair. The invention discloses the application of the DRIL molecules as adjuvant compositions to be used in association with a DNA breaking treatment, particularly radiotherapy or chemotherapy, in combination with a pharmaceutically acceptable carrier, in an efficient amount to be introduced in the tumoral cell nuclei in order to trigger DNA repair induced lethality (DRIL in short) of tumoral cells/tissues.